Company intelligence / Profile preview

Aeromics, Inc.

Branford, Connecticut, United Statesaeromics.com ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Aeromics is developing AER-271, an intravenously administered aquaporin-4 inhibitor designed to prevent or arrest brain swelling in patients suffering from acute ischemic stroke. The company has partnered with Simcere for development in Greater China, where the drug (designated SIM0307) has begun first-in-human dosing. Aeromics is preparing for its own Phase IIa proof-of-mechanism trial in the United States.

Therapeutic areas: Neurology
Modalities: Small molecules (AQP4 inhibitor)
Industry: Biotech

Drug pipeline

1 asset

AER-271

Partnerships

Simcere (for development and commercialization in Greater China)

Beyond the preview

Go deeper on Aeromics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aeromics, Inc..